Predictive Value of Peripheral Blood Markers in Hepatocellular Carcinoma Patients Treated with Anti-PD-1 in Combination with Targeted Therapy — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Predictive Value of Peripheral Blood Markers in Hepatocellular Carcinoma Patients Treated with Anti-PD-1 in Combination with Targeted Therapy
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
,
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Background: There are currently no recognised biomarkers that identify predictive groups of benefit in patients with hepatocellular carcinoma receiving immune-combined targeted therapy, for which we explored the value of peripheral blood markers as markers of their prognosis. Methods: Patients who underwent anti-PD-1 combination targeted therapy for hepatocellular carcinoma from 1 January 2019 to 31 December 2021 at the First Affiliated Hospital of Chongqing Medical University were retrospectively analysed. The data collected were analysed by R software. Results: A total of 41 cases were included in our study. The optimal threshold values of peripheral blood markers were obtained by plotting ROC curves and grouping patients. Survival analysis of the grouped patients showed statistically significant differences in survival between the different groups for Platelet-lymphocyte ratio (PLR, P = 0.0022), Monocyte-lymphocyte ratio (MLR, P = 0.042), Fibrinogen-Lymphocyte Ratio (FLR, P = 0.0009), Prognostic nutritional index (PIN, P = 0.0005), and Fibrinogen-albumin ratio (FAR, P = 0.0144). An ANOVA was performed on the basic conditions of the patients between the different groups, except for the statistically significant difference in BCLC stage (P = 0.0128) between the high MLR and low MLR groups, there was no statistically significant difference in age, gender, BCLC stage, and hepatitis status between the groups. COX regression analysis showed that BCLC stage, FAR, FLR and PIN were risk factors associated with the prognosis of patients receiving targeted combination immunotherapy for hepatocellular carcinoma, and FLR was an independent risk factor associated with the prognosis of patients receiving targeted combination immunotherapy for hepatocellular carcinoma. Conclusions: We found that peripheral blood markers are promising biomarkers for predicting the prognosis of patients with hepatocellular carcinoma receiving anti-PD-1 combined with targeted therapy, and this study identified FLR as an independent risk factor for the prognosis of patients having advanced hepatocellular carcinoma treated with anti-PD-1 combined with targeted therapy.
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., et al. (2021) Hepatocellular Carcinoma. Nature Reviews Disease Primers, 7, Article No. 6. https://doi.org/10.1038/s41572-020-00240-3
Rumgay, H., Arnold, M., Ferlay, J., Lesi, O., Cabasag, C.J., Vignat, J., et al. (2022) Global Burden of Primary Liver Cancer in 2020 and Predictions to 2040. Journal of Hepatology, 77, 1598-1606. https://doi.org/10.1016/j.jhep.2022.08.021
Reig, M., Forner, A., Rimola, J., Ferrer-Fabrega, J., Burrel, M., Garcia-Criado, A., et al. (2022) BCLC Strategy for Prognosis Prediction and Treatment Recommendation: The 2022 Update. Journal of Hepatology, 76, 681-693. https://doi.org/10.1016/j.jhep.2021.11.018
Galle, P.R., Finn, R.S., Qin, S., Ikeda, M., Zhu, A.X., Kim, T.Y., et al. (2021) Patient-Reported Outcomes with Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma (IMbrave150): An Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 22, 991-1001. https://doi.org/10.1016/S1470-2045(21)00151-0
An, H.J., Chon, H.J. and Kim, C. (2021) Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 22, Article No. 9414. https://doi.org/10.3390/ijms22179414
Myojin, Y., Kodama, T., Sakamori, R., Maesaka, K., Matsumae, T., Sawai, Y., et al. (2022) Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy. Cancers, 14, Article No. 883. https://doi.org/10.3390/cancers14040883
Pallozzi, M., Di Tommaso, N., Maccauro, V., Santopaolo, F., Gasbarrini, A., Ponziani, F.R., et al. (2022) Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Cancers, 14, Article No. 4631. https://doi.org/10.3390/cancers14194631
He, Y., Lu, M., Che, J., Chu, Q., Zhang, P. and Chen, Y. (2021) Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Frontiers in Oncology, 11, Article 716844. https://doi.org/10.3389/fonc.2021.716844
Nakano, M., Kuromatsu, R., Niizeki, T., Okamura, S., Iwamoto, H., Shimose, S., et al. (2021) Immunological Inflammatory Biomarkers as Prognostic Predictors for Advanced Hepatocellular Carcinoma. ESMO Open, 6, Article ID: 100020. https://doi.org/10.1016/j.esmoop.2020.100020
Li, Y., Li, Z., Deng, K., Liao, M., Yuan, S. and Huang, Z. (2020) Fibrinogen/Lymphocyte Count Ratio Can Be Used as a New Indicator of Prognosis in Patients with Hepatocellular Carcinoma after Radical Resection. Cancer Management and Research, 12, 9057-9066. https://doi.org/10.2147/CMAR.S266653
Dharmapuri, S., Ozbek, U., Lin, J.-Y., Sung, M., Schwartz, M., Branch, A.D., et al. (2020) Predictive Value of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Advanced Hepatocellular Carcinoma Patients Treated with Anti -PD-1 Therapy. Cancer Medicine, 9, 4962-4970. https://doi.org/10.1002/cam4.3135
Bilen, M.A., Martini, D.J., Liu, Y., Lewis, C., Collins, H.H., Shabto, J.M., et al. (2019) The Prognostic and Predictive Impact of Inflammatory Biomarkers in Patients Who Have Advanced-Stage Cancer Treated with Immunotherapy. Cancer, 125, 127-134. https://doi.org/10.1002/cncr.31778
Chen, W., Zhang, M., Chen, C. and Pang, X. (2022) Prognostic Nutritional Index and Neutrophil/Lymphocyte Ratio Can Serve as Independent Predictors of the Prognosis of Hepatocellular Carcinoma Patients Receiving Targeted Therapy. Journal of Oncology, 2022, Article ID: 1389049. https://doi.org/10.1155/2022/1389049
Guo, Z. and Liang, J. (2021) Fibrinogen-Albumin Ratio Index (FARI) as a Certain Prognostic Biomarker in Pretreated Patients with Immunotherapy. Cancer Management and Research, 13, 4169-4180. https://doi.org/10.2147/CMAR.S307272
Hartke, J., Johnson, M. and Ghabril, M. (2017) The Diagnosis and Treatment of Hepatocellular Carcinoma. Seminars in Diagnostic Pathology, 34, 153-159. https://doi.org/10.1053/j.semdp.2016.12.011
European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236.
Yan, D., Shen, Z., Zhang, S., Hu, L., Sun, Q., Xu, K., et al. (2021) Prognostic Values of Geriatric Nutritional Risk Index (GNRI) and Prognostic Nutritional Index (PNI) in Elderly Patients with Diffuse Large B-Cell Lymphoma. Journal of Cancer, 12, 7010-7017. https://doi.org/10.7150/jca.62340
Yang, Y.M., Kim, S.Y. and Seki, E. (2019) Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets. Seminars in Liver Disease, 39, 26-42. https://doi.org/10.1055/s-0038-1676806
Ray, K. (2018) Liver Cancer: A Complex Interplay between Inflammation and Immunity in Liver Cancer. Nature Reviews Gastroenterology & Hepatology, 15, 3. https://doi.org/10.1038/nrgastro.2017.165
Ji, R., Ren, Q., Bai, S., Wang, Y. and Zhou, Y. (2018) Prognostic Significance of Pretreatment Plasma Fibrinogen Level in Patients with Digestive System Tumors: A Meta-Analysis. The International Journal of Biological Markers, 33, 254-265. https://doi.org/10.1177/1724600818773627
Asanuma, K., Matsumine, A., Nakamura, T., Matsubara, T., Asanuma, Y., Oi, T., et al. (2016) Impact of Plasma Fibrinogen Levels in Benign and Malignant Soft Tissue Tumors. Cancer Biomarkers, 16, 453-458. https://doi.org/10.3233/CBM-160584
Luyendyk, J.P., Schoenecker, J.G. and Flick, M.J. (2019) The Multifaceted Role of Fibrinogen in Tissue Injury and Inflammation. Blood, 133, 511-520. https://doi.org/10.1182/blood-2018-07-818211
Qi, Q., Geng, Y., Sun, M., Chen, H., Wang, P. and Chen, Z. (2015) Hyperfibrinogen Is Associated with the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer. Pancreas, 44, 977-982. https://doi.org/10.1097/MPA.0000000000000353
Kudo, M. (2020) Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers, 12, Article No. 1089. https://doi.org/10.3390/cancers12051089
Oura, K., Morishita, A., Tani, J. and Masaki, T. (2021) Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. International Journal of Molecular Sciences, 22, Article No. 5801. https://doi.org/10.3390/ijms22115801
Kang, S.M., Khalil, L., El-Rayes, B.F. and Akce, M. (2022) Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. Frontiers in Oncology, 12, Article 821903. https://doi.org/10.3389/fonc.2022.821903
Ang, C., Klempner, S.J., Ali, S.M., Madison, R., Ross, J.S., Severson, E.A., et al. (2019) Prevalence of Established and Emerging Biomarkers of Immune Checkpoint Inhibitor Response in Advanced Hepatocellular Carcinoma. Oncotarget, 10, 4018-4025. https://doi.org/10.18632/oncotarget.26998
Mukai, S., Kanzaki, H., Ogasawara, S., Ishino, T., Ogawa, K., Nakagawa, M., et al. (2021) Exploring Microsatellite Instability in Patients with Advanced Hepatocellular Carcinoma and Its Tumor Microenvironment. JGH Open, 5, 1266-1274. https://doi.org/10.1002/jgh3.12660
Wong, M., Kim, J.T., Cox, B., Larson, B.K., Kim, S., Waters, K.M., et al. (2021) Evaluation of Tumor Mutational Burden in Small Early Hepatocellular Carcinoma and Progressed Hepatocellular Carcinoma. Hepatic Oncology, 8, Article No. HEP39. https://doi.org/10.2217/hep-2020-0034